Holen Sie sich die Stockscreener-App
0.5001
1.92%
-0.0098
Vorhandelsmarkt:
.51
0.0099
+1.98%
Schlusskurs vom Vortag:
$0.5099
Offen:
$0.5099
24-Stunden-Volumen:
696.99K
Relative Volume:
1.00
Marktkapitalisierung:
$19.16M
Einnahmen:
$1.50M
Nettoeinkommen (Verlust:
$-64.59M
KGV:
-0.2995
EPS:
-1.67
Netto-Cashflow:
$-55.17M
1W Leistung:
-3.70%
1M Leistung:
-85.12%
6M Leistung:
-76.74%
1J Leistung:
-85.46%
1-Tages-Spanne:
$0.48
$0.5099
1-Wochen-Bereich:
$0.48
$0.5689
52-Wochen-Spanne:
$0.48
$4.79
Leap Therapeutics Inc Stock (LPTX) Company Profile
Firmenname
Leap Therapeutics Inc
Sektor
Branche
Telefon
617 252 4343
Adresse
47 THORNDIKE STREET, CAMBRIDGE, MA
Vergleichen Sie LPTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LPTX
Leap Therapeutics Inc
|
0.5001 | 19.16M | 1.50M | -64.59M | -55.17M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Leap Therapeutics Inc Stock (LPTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-01-29 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2021-10-04 | Eingeleitet | Mizuho | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2020-06-29 | Eingeleitet | Piper Sandler | Overweight |
| 2020-02-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-11-15 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-09-13 | Fortgesetzt | Raymond James | Outperform |
| 2017-03-07 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Leap Therapeutics Inc Aktie (LPTX) Neueste Nachrichten
Get in on Leap Therapeutics Inc’s (LPTX) buy-in window today! - SETE News
Leap Therapeutics Inc (LPTX) stock analysis: A simple moving average approach - US Post News
What is HC Wainwright's Estimate for LPTX FY2029 Earnings? - MarketBeat
Leap Therapeutics (NASDAQ:LPTX) Downgraded by Baird R W to "Hold" - MarketBeat
Leap Therapeutics (NASDAQ:LPTX) Downgraded to "Neutral" Rating by HC Wainwright - MarketBeat
Leap Therapeutics (NASDAQ:LPTX) Cut to "Neutral" at Robert W. Baird - MarketBeat
FY2029 Earnings Estimate for LPTX Issued By HC Wainwright - Defense World
Robert W. Baird Downgrades Leap Therapeutics (NASDAQ:LPTX) to Neutral - Defense World
Leap Therapeutics (NASDAQ:LPTX) Rating Lowered to “Neutral” at HC Wainwright - Defense World
Leap Therapeutics Reports Promising Initial Clinical Data, Updates Corporate Presentation - Defense World
Baird R W Downgrades Leap Therapeutics (NASDAQ:LPTX) to Hold - Defense World
Leap reports positive colorectal cancer study results - MSN
Leap Therapeutics stock rating cut by H.C. Wainwright to Neutral - MSN
Baird cuts Leap Therapeutics stock rating, slashes target - MSN
Leap Therapeutics stock hits 52-week low at $0.8 - MSN
Leap Therapeutics cut to Neutral at Baird after mid-stage trial setback - MSN
Leap Therapeutics Shares Tumble After Downgrades from Baird, HC Wainwright -January 29, 2025 at 03:02 pm EST - Marketscreener.com
Leap Therapeutics stock cut to Neutral at Baird (LPTX:NASDAQ) - Seeking Alpha
This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Baird Downgrades Leap Therapeutics to Neutral From Outperform, Cuts Price Target to $1.25 From $9 - Marketscreener.com
HC Wainwright Downgrades Leap Therapeutics to Neutral From Buy -January 29, 2025 at 07:17 am EST - Marketscreener.com
Leap halts gastric cancer program, changes course - The Pharma Letter
Leap Therapeutics Stock Plunges To Record Low After Ending Gastric Cancer Drug Trials, Retail Bets On CRC Pipeline - MSN
Leap Therapeutics stock hits 52-week low at $0.8 By Investing.com - Investing.com Nigeria
Health Care Cos Down Amid Rotation into Tech -- Health Care Roundup -January 28, 2025 at 05:45 pm EST - Marketscreener.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Leap Therapeutics Shares Drop After Discontinuing Phase 3 Studies of Gastric Cancer Treatment - Marketscreener.com
Leap Therapeutics Stock Plunges To Record Low After Ending Gastric Cancer Drug Trials, Retail Bets On CRC Pipe - Asianet Newsable
Leap Therapeutics stock plummets as it will discontinue DisTinGuish study in advanced gastric cancer - MSN
Why Is Leap Therapeutics Stock Trading Lower On Tuesday?Leap Therapeutics (NASDAQ:LPTX) - Benzinga
Gold Gains 1%; Boeing Shares Rise Following Q4 Results - Benzinga
Leap Therapeutics: 2 Cancer Trials Disappoint, But There Is A Silver Lining (NASDAQ:LPTX) - Seeking Alpha
Stock market news: Vincerx Pharma plunged by 95.86% while MiNK Therapeutics was down by 94.26% during mid day trading - Business Upturn
Nasdaq Surges More Than 300 Points; Lockheed Martin Shares Dip After Q4 Results - Benzinga
Stock market today: Vincerx Pharma declined by 95.75% whereas Revelation Biosciences - Business Upturn
Dow Gains Over 50 Points; General Motors Posts Upbeat Earnings - Benzinga
Leap reports positive colorectal cancer study results By Investing.com - Investing.com South Africa
Leap crashes as midphase data mark end of gastric cancer program - Fierce Biotech
Leap Therapeutics Shares Slide After Initial Mid-Stage Cancer-Drug Results - MarketWatch
Leap stock tumbles on mid-stage trial setback (LPTX:NASDAQ) - Seeking Alpha
Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study - Yahoo Finance
Delayed Dream Sleep Linked to Alzheimer's Risk - 69News WFMZ-TV
Finanzdaten der Leap Therapeutics Inc-Aktie (LPTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.82%
0.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):